Anti-cancer Drug Shows Early Promise In Pulmonary Hypertension

"We are excited about this finding because there are so few treatment options for pulmonary hypertension," said study author Mardi Gomberg-Maitland, M.D., M.Sc., assistant professor of medicine at the University of Chicago. "We have drugs that can slow progression of the disease but nothing that can stop or reverse the process. This is a ray of hope."

Pulmonary hypertension and cancer share certain features. Both diseases involve abnormal cellular growth. These abnormal cells -- in the case of pulmonary hypertension, those that line the blood vessels leading to the lungs -- release signals that stimulate the growth of small new blood vessels to feed the renegade cells, allowing further proliferation, and thickening of the vessel walls. Sorafenib appears to interfere with that process.

Although originally designed to fight colon cancer, the drug, sorafenib (Nexavar®), proved much more effective against kidney cancer. Sorafenib inhibits an enzyme, known as Raf kinase, which plays a role in tumor-cell growth. Researchers eventually realized it also hit other targets. After clinical trials in kidney cancer patients demonstrated improved survival, it won FDA approval in December 2005.

Now, in a surprise finding, it appears to have a use in treating this cardiovascular disease.

In pulmonary hypertension, the vessels that carry blood from the heart to the lungs constrict. Their walls thicken, which narrows the opening and reduces blood flow. Pressures within the arteries build up, requiring the heart to pump harder to push blood through the narrowed tubes to the lungs. Eventually the heart can no longer keep up. Less and less blood reaches the lungs, the heart enlarges to try to overcome the pressure, and damage to the overworked heart accumulates.

Although treatment for pulmonary hypertension has improved, long-term survival, even with therapy, is disappointing, similar to that for lung cancer. Because sorafenib inhibits the chemical signals that can trigger both cellular proliferation and new blood vessel growth, Gomberg-Maitland and colleagues suspected it might slow the growth and thickening of the pulmonary artery walls.

To test this theory they treated rats at high risk for pulmonary hypertension with sorafenib. The researchers studied five groups of rats. One group stayed in normal cages and received no medication. The other four groups spent three weeks in a low-oxygen environment -- about half the normal level -- which can trigger pulmonary hypertension. Rats in the reduced-oxygen chambers received: no medication, a drug called SU5416 (well known to cause severe pulmonary hypertension in this setting), SU5416 plus sorafenib, or sorafenib alone.

As expected, the unmedicated rats in a low-oxygen environment had mildly elevated pulmonary artery pressures after three weeks and those that received SU5416 developed severe pulmonary hypertension. But, those that received sorafenib or sorafenib plus S5416, had negligible pressure increases. Sorafenib appeared not only to counteract the effects of the low-oxygen environment but also to prevent the additional damage caused by SU5416.

"This was an encouraging sign," said Gomberg-Maitland. This is "one of the best models we have for this disease," she said.

The side effects of the drug in humans have been relatively mild. The most common adverse effects are: rashes of the face and arms or hands and feet, mild diarrhea, and fatigue.

A phase-1 clinical trial of the drug in human patients with pulmonary hypertension is expected to begin this winter.